Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

2

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Muscarinic acetylcholine receptor M3

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

2

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

2004

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Overactive bladder

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Palliative

2

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

2

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Pfizer

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

2

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

2

CHEBI

2

ChEMBL

2

DAILYMED

2

DRUG BANK

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

GENITO URINARY SYSTEM AND SEX HORMONES

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

UROLOGICALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

OTHER UROLOGICALS, INCL. ANTISPASMODICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Urinary antispasmodics

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

1

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 2 of 2 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

DARIFENACIN

APG9819VLM

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First approved in 2004

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Muscarinic acetylcholine receptor M3

Conditions:

Overactive bladder

Darifenacin is a selective muscarinic receptor M3 antagonist which was approved by FDA for the treatment of overactive bladder.

DARIFENACIN HYDROBROMIDE

CR02EYQ8GV

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First approved in 2004

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Muscarinic acetylcholine receptor M3

Conditions:

Overactive bladder

Darifenacin is a selective muscarinic receptor M3 antagonist which was approved by FDA for the treatment of overactive bladder.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1